

{Glp}-RPRLSHKGPMPF



# **Data Sheet**

Product Name: [Pyr1]-Apelin-13

 Cat. No.:
 CS-7600

 CAS No.:
 217082-60-5

Molecular Formula: C69H108N22O16S

Molecular Weight: 1533.80

Target: Others
Pathway: Others

**Solubility:**  $H2O : \geq 50 \text{ mg/mL } (32.60 \text{ mM})$ 

### **BIOLOGICAL ACTIVITY:**

[Pyr1]-Apelin-13 is a highly potent, selective endogenous apelin receptor (APJ) agonist. **In Vitro**: [Pyr1]-apelin-13 encapsulation in lipoPEG particles (lipoPEG-PA13) results in sustained and extended drug release under physiological conditions<sup>[1]</sup>. **In Vivo**: [Pyr1]-apelin-13 nanocarriers in a mouse model of pressure-overload induced heart failure demonstrate a sustainable long-term effect of [Pyr1]-apelin-13 in preventing cardiac dysfunction<sup>[1]</sup>. [Pyr1] apelin-13 (1, 5  $\mu$ g) improves locomotor activity and reduces pain symptoms, cavity size and caspase-3 levels in rats. [Pyr1] apelin-13 (1, 5  $\mu$ g) significantly increases thermal paw withdrawal latency. [Pyr1] apelin-13 in 5  $\mu$ g dose also produces significant attenuation in paw withdrawal threshold compared to SCI animals from the second week post SCI<sup>[2]</sup>.

### References:

- [1]. Serpooshan V, et al. [Pyr1]-Apelin-13 delivery via nano-liposomal encapsulation attenuates pressure overload-induced cardiac dysfunction. Biomaterials. 2015 Jan;37:289-98.
- [2]. Hajimashhadi Z, et al. Chronic administration of [Pyr1] apelin-13 attenuates neuropathic pain after compression spinal cord injury in rats. Neuropeptides. 2017 Feb;61:15-22.

## **CAIndexNames:**

L-Phenylalanine, 5-oxo-L-prolyl-L-arginyl-L-prolyl-L-arginyl-L-leucyl-L-seryl-L-histidyl-L-lysylglycyl-L-prolyl-L-methionyl-L-prolyl-

### **SMILES:**

[{Glp}-RPRLSHKGPMPF]

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 732-484-9848 Fax: 888-484-5008 E-mail: sales@ChemScene.com Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

Page 1 of 1 www.ChemScene.com